Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Histamine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    198 result(s) found for: Histamine. Displaying page 9 of 10.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next»
    EudraCT Number: 2006-005868-10 Sponsor Protocol Number: 6043-PG-PSC-153 Start Date*: 2007-07-24
    Sponsor Name:Laboratorios LETI S.L.
    Full Title: Ensayo clínico, multicéntrico, aleatorizado, doble ciego controlado con placebo, de inmunoterapia subcutánea con extracto despigmentado y polimerizado de polen de Phleum pratense en pacientes con h...
    Medical condition: Rinoconjuntivitis moderada-severa (con o sin asma episódico) inducida por hipersensibilidad frente al polen de gramíneas.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039097 Rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-006533-19 Sponsor Protocol Number: SC-312A Start Date*: 2022-11-15
    Sponsor Name:ROXALL Medizin GmbH
    Full Title: Phase II-III study to assess the efficacy and safety of subcutaneous cluster-immunotherapy in patients suffering from grass pollen allergy
    Medical condition: Patients with grass pollen-related allergic rhinitis/rhinoconjunctivitis and well-controlled mild-to-moderate or without asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10039085 Rhinitis allergic PT
    20.0 10015919 - Eye disorders 10010744 Conjunctivitis allergic PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001785-95 Sponsor Protocol Number: BTA798-203 Start Date*: 2015-03-16
    Sponsor Name:Biota Pharmaceuticals, Inc.
    Full Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Dose-ranging Study of Vapendavir in Moderate to Severe Asthmatic Adults with Symptomatic Human Rhinovirus Infection.
    Medical condition: Asthma control following presumptive human rhinovirus (HRV) infection in moderate and severe asthma subjects, as measured by the Asthma Control Questionnaire (ACQ-6).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-000333-31 Sponsor Protocol Number: PQGrass205 Start Date*: 2017-09-13
    Sponsor Name:Allergy Therapeutics (UK) Ltd.
    Full Title: A multi-centre, randomised, double blind, placebo controlled study to determine the optimal effective and safe dose of Pollinex Quattro Grass 1.0 mL (Allergy Therapeutics, (UK) Ltd.) for the treatm...
    Medical condition: Grass pollen-induced seasonal allergic rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-004336-28 Sponsor Protocol Number: PQBirch203 Start Date*: 2013-08-19
    Sponsor Name:Allergy Therapeutics (UK) Ltd.
    Full Title: A multi-centre, double-blind dose-ranging study to evaluate the efficacy and safety/tolerability of Birch Modified Allergen Tyrosine-adsorbed + MPL (POLLINEX Quattro® Birch) in Subjects with season...
    Medical condition: seasonal allergic rhinoconjunctivitis due to birch pollen
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-006545-41 Sponsor Protocol Number: PPD/2007/AER 001 DPI/2b Start Date*: 2009-03-20
    Sponsor Name:Aerovance, Inc
    Full Title: A PHASE IIB STUDY TO INVESTIGATE THE TREATMENT-SPARING EFFECTS OF AEROVANT™ (AER 001 INHALATION POWDER) IN ASTHMA PATIENTS NOT FULLY CONTROLLED ON CURRENT THERAPY
    Medical condition: moderate persistent to severe persistent asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003553 Asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000548-25 Sponsor Protocol Number: AL1605av Start Date*: 2018-06-18
    Sponsor Name:Allergopharma GmbH & Co. KG
    Full Title: A multicentre, randomized, open label clinical trial for safety evaluation of an accelerated high dose escalation schedule with one strength for an allergen immunotherapy with an aluminium hydroxid...
    Medical condition: Patients with moderate to severe seasonal rhinitis or rhinoconjunctivitis with or without asthma
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004870 10039776 Seasonal allergic rhinitis LLT
    20.0 100000004870 10001726 Allergic rhinitis due to pollen LLT
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    21.1 100000004855 10001705 Allergic asthma LLT
    21.1 100000004855 10001723 Allergic rhinitis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-003679-23 Sponsor Protocol Number: EPITOPE-V712-304 Start Date*: Information not available in EudraCT
    Sponsor Name:DBV TECHNOLOGIES S.A.
    Full Title: A double-blind, placebo-controlled, randomized phase III trial to assess the safety and efficacy of Viaskin® Peanut in peanut-allergic young children 1-3 years of age (EPITOPE study)
    Medical condition: Peanut allergy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004870 10034202 Peanut allergy LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: IE (Completed) FR (Ongoing) DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-011504-36 Sponsor Protocol Number: AL0906rP Start Date*: 2010-02-02
    Sponsor Name:Allergopharma Joachim Ganzer KG
    Full Title: Randomised double blind placebo controlled pivotal study to evaluate efficacy and safety of rPhleum in adult and adolescent patients suffering from rhinoconjunctivitis +/- controlled Asthma
    Medical condition: ICD classification code: J45.0 and J 30.1 Rhiniconjunctivitis +/- asthma bronchiale
    Disease: Version SOC Term Classification Code Term Level
    15.0 10038738 - Respiratory, thoracic and mediastinal disorders 10039085 Rhinitis allergic PT
    15.0 10038738 - Respiratory, thoracic and mediastinal disorders 10001705 Allergic asthma LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) PL (Completed) FR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-005550-30 Sponsor Protocol Number: SB/0042 Start Date*: 2014-06-10
    Sponsor Name:HAL Allergy B.V.
    Full Title: A randomized, double-blind, placebo-controlled (DBPC), parallel group study to assess the clinical efficacy and safety of SUBLIVAC FIX Birch immunotherapy in patients suffering from allergic rhinit...
    Medical condition: Moderate to severe birch pollen induced allergic rhinitis/rhinoconjunctivitis with or without mild to moderate persistent asthma.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004870 10001726 Allergic rhinitis due to pollen LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) SK (Completed) BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-000051-27 Sponsor Protocol Number: PM/0041 Start Date*: 2016-09-22
    Sponsor Name:HAL Allergy B.V.
    Full Title: A randomized, double-blind, placebo-controlled (DBPC) parallel-group multi-centre study to assess the efficacy and safety of PURETHAL Mites subcutaneous immunotherapy (SCIT) in patients with allerg...
    Medical condition: Allergic rhinitis/rhinoconjunctivitis (ARC) caused by house dust mite (HDM) allergy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    20.0 100000004855 10001724 Allergic rhinitis (excl hay fever) LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) SK (Completed) HU (Completed) ES (Completed) BE (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2015-002105-11 Sponsor Protocol Number: BTT-gpASIT009 Start Date*: 2015-11-10
    Sponsor Name:BioTech Tools S.A.
    Full Title: A multicenter, international, randomised, double-blind, placebo controlled study to demonstrate the clinical efficacy and safety of a subcutaneous immunotherapy with gpASIT+™ in patients with grass...
    Medical condition: Treatment of seasonal grass pollen rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004870 10019170 Hay fever LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) CZ (Completed) ES (Completed) FR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003323-10 Sponsor Protocol Number: V712-305(EPOPEX) Start Date*: Information not available in EudraCT
    Sponsor Name:DBV TECHNOLOGIES S.A.
    Full Title: EPITOPE OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM CLINICAL BENEFIT AND SAFETY OF DBV712 IN PEANUT-ALLERGIC CHILDREN (EPOPEX)
    Medical condition: Peanut allergy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004870 10034202 Peanut allergy LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: IE (Completed) GB (GB - no longer in EU/EEA) NL (Trial now transitioned) DE (Trial now transitioned) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019373-15 Sponsor Protocol Number: 291202BS Start Date*: 2010-06-15
    Sponsor Name:Marinomed Biotechnologie GmbH
    Full Title: A phase IIa, single-center, randomized, reference-controlled, observer-blind trial to assess the efficacy of a topical Aescin formulation in experimentally induced itch, wheal and flare reactions i...
    Medical condition: subjects with proven type I allergy against one of the three allergens: grass pollen, tree pollen, cat epithelia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10036019 Pollen allergy LLT
    12.1 10066093 Birch pollen allergy LLT
    12.1 10001742 Allergy to animal LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000672-42 Sponsor Protocol Number: BIA-STD-003 Start Date*: 2012-10-11
    Sponsor Name:Bial Industrial Farmacéutica S.A.
    Full Title: Biological standardization of allergen extracts of pollen of Artemisa vulgaris and Platanus acerifolia and the acarus Dermatophagoides farinae in patients sensitized to them.
    Medical condition: Treatment and diagnosis of allergy to Artemisa vulgaris, Platanus acerifolia and Dermatophagoides farinae.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10036019 Pollen allergy LLT
    14.1 10021428 - Immune system disorders 10066092 Acaridae allergy LLT
    14.1 10021428 - Immune system disorders 10048908 Seasonal allergy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005823-35 Sponsor Protocol Number: 20201206 Start Date*: 2021-01-28
    Sponsor Name:Aarhus Universitet [...]
    1. Aarhus Universitet
    2. Aarhus Universitet
    3. Aarhus Universitet
    4. Aarhus Universitet
    Full Title: ILIT.FT – Dose finding for intralymphatic allergen immunotherapy in a randomized, parallel group, double blind placebo-controlled field trial
    Medical condition: Allergic rhinitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10039085 Rhinitis allergic PT
    20.0 10015919 - Eye disorders 10010744 Conjunctivitis allergic PT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002296-42 Sponsor Protocol Number: SC-21A Start Date*: 2020-01-31
    Sponsor Name:ROXALL Medizin GmbH
    Full Title: Phase II study to assess the tolerability, safety and efficacy of subcutaneous cluster-immunotherapy in patients suffering from birch pollen allergy
    Medical condition: Allergic rhinitis / rhino-conjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10001723 Allergic rhinitis LLT
    20.0 100000004870 10001726 Allergic rhinitis due to pollen LLT
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    20.1 100000004870 10066093 Birch pollen allergy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002319-27 Sponsor Protocol Number: SL-61A Start Date*: 2021-02-01
    Sponsor Name:ROXALL Medizin GmbH
    Full Title: Phase II study to assess the tolerability, safety and efficacy of sublingual immunotherapy in patients suffering from birch pollen allergy
    Medical condition: Birch pollen-related allergic rhinitis / rhino-conjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10001723 Allergic rhinitis LLT
    20.0 100000004870 10001726 Allergic rhinitis due to pollen LLT
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    20.1 100000004870 10066093 Birch pollen allergy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002881-42 Sponsor Protocol Number: SL-351A Start Date*: 2023-02-07
    Sponsor Name:ROXALL Medizin GmbH
    Full Title: Phase II study to assess the tolerability, safety and efficacy of sublingual immunotherapy in patients suffering from grass pollen allergy
    Medical condition: Patients with grass pollen-related allergic rhinitis/rhino-conjunctivitis (with well-controlled mild-to-moderate or without asthma)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10001723 Allergic rhinitis LLT
    20.0 100000004870 10001726 Allergic rhinitis due to pollen LLT
    20.0 100000004853 10001709 Allergic conjunctivitis LLT
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005169-41 Sponsor Protocol Number: SL-372A Start Date*: 2023-03-16
    Sponsor Name:ROXALL Medizin GmbH
    Full Title: Phase II-III study to assess efficacy and safety of sublingual immunotherapy in patients suffering from house dust mite allergy
    Medical condition: Patients with house dust mites related allergic rhinitis/rhinoconjunctivitis and well-controlled mild-to-moderate or without asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10039085 Rhinitis allergic PT
    20.0 10015919 - Eye disorders 10010744 Conjunctivitis allergic PT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 10:31:05 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA